LLY 📈 Eli Lilly - Overview

Eli Lilly and Company is a global pharmaceutical entity that engages in the discovery, development, and marketing of a wide range of human pharmaceuticals. The company's product portfolio includes an array of treatments for diabetes, such as Basaglar, Humalog, and Humulin, which cater to the diverse needs of patients with this condition. Additionally, it offers Jardiance, Mounjaro, and Trulicity for type 2 diabetes management, as well as Zepbound for obesity treatment. This comprehensive approach to addressing diabetes and obesity underscores the company's commitment to improving patient outcomes in these areas.

Beyond its diabetes and obesity treatments, Eli Lilly and Company has a significant presence in the field of oncology. Its product lineup in this area includes Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, which are used to treat various types of cancer. The company also offers treatments for other conditions, including rheumatoid arthritis, atopic dermatitis, and severe alopecia areata, with products like Olumiant. Taltz is another key product, used for the treatment of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Furthermore, the company provides Omvoh for ulcerative colitis, Cymbalta for depressive disorder and other conditions, Ebglyss for severe atopic dermatitis, and Emgality for migraine prevention and episodic cluster headache.

In the realm of men's health and osteoporosis, Eli Lilly and Company offers Cialis for erectile dysfunction and benign prostatic hyperplasia, as well as Forteo for osteoporosis treatment. The company's dedication to innovation is further exemplified by its operation of the Lilly Seaport Innovation Center (LSC) in Boston. This research and development facility is focused on advancing RNA and DNA-based therapies and discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. Through collaborations with other pharmaceutical companies and research institutions, such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd, Eli Lilly and Company continues to expand its capabilities and push the boundaries of medical science.

With a history dating back to 1876, Eli Lilly and Company is headquartered in Indianapolis, Indiana, and is publicly traded on the New York Stock Exchange (NYSE) under the ticker symbol LLY. The company's common stock is classified under the GICS Sub Industry: Pharmaceuticals, and its ISIN is US5324571083. As a major player in the pharmaceutical industry, Eli Lilly and Company remains committed to developing and marketing innovative treatments that improve patient outcomes and address some of the world's most pressing health challenges. For more information, the company's website can be accessed at https://www.lilly.com.